ArticleCancers2022

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon

Hong-Shuai Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.